March 08, 2019

New Trogarzo® Data Presented at Conference on Retroviruses and Opportunistic Infections Demonstrates Sustained Viral Suppression at Week 96

Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that new data, presented today at the 26th annual Conference on Retroviruses and Opportunistic Infections (CROI), show that Trogarzo® (ibalizumab-uiyk) injection maintains viral suppression at week 96.